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Efficacy of Clomipramine, Sertraline and Terazosin
Treatments in Premature Ejaculation
Aim: To compare the efficacy of oral clomipramine, sertraline and terazosin to placebo in premature
ejaculation.
Materials and Methods: A total of 90 patients aged from 20 to 58 years were enrolled in this study. Patients
were randomized into 4 groups. Group 1 (n: 22) took placebo and served as controls. Group 2 (n: 23) patients
took 25 mg clomipramine HCl nightly; Group 3 (n: 20)
50 mg sertraline nightly; and Group 4 (n: 25) 5 mg terazosin nightly. The medications were used for two
months. After 8 sexual attempts, the patients' clinical responses were assessed using the patient selfdescription method. Clinical responses were classified as “no change”, “improvement” and “under control”.
Success was described as improvement + under control.
Results: Success rates were 36.3% in Group 1, 91.3% in Group 2, 90% in Group 3 and 76% in Group 4.
Although the efficacy of each medical treatment was superior to placebo (P = 0.001), no significant difference
in efficacy was found between the medical treatment groups (P = 0.537).
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Conclusions: Clomipramine, sertraline and terazosin are more efficient than placebo. No significant difference
was observed in terms of efficacy among these three medical treatments.
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Prematür Ejakülasyonda Klomipramin, Sertralin ve
Terazosin Tedavilerinin Etkinli¤i
Amaç: Prematür ejakülasyonda klomipramin, sertralin ve terazosin etkinli¤ini plasebo ile karﬂ›laﬂt›rmak.
Yöntem ve Gereç: Yaﬂlar› 20 ile 98 aras›nda olan 90 hasta çal›ﬂmaya al›nd›. Hastalar randomize olarak 4
gruba ayr›ld›lar. Grup 1’deki 22 hastaya placebo verildi. Grup 2, 23 hastadan oluﬂuyordu ve her gece 25mg
Klomipramin ald›. Grup 3’teki 20 hasta her gece 50mg Sertralin kulland›. Grup 4’teki 25 hasta ise her gece
5mg Terazosin kulland›. Her tedavi iki ay süre ile kullan›ld›. Sekiz kez cinsel iliﬂki sonras›nda hastalar›n klinik
yan›t› kendi kendine tan›mlama yöntemi ile yap›ld›. Klinik yan›tlar “yan›t yok”, “geliﬂme var” ve “kontrol
alt›nda” ﬂeklinde s›n›fland›. Tedavi baﬂar›s› ise geliﬂme var ve kontrol alt›nda yan›tlar›n›n toplam› olarak
tan›mland›.
Bulgular: Baﬂar› oranlar› Grup 1’de % 36.3, Grup 2’de % 91.3, Grup 3’de % 90, Grup 4’te ise % 76 idi.
Her bir medikal tedavi plasebo’ya üstünlük göstermesine ra¤men (P = 0.001), her bir medikal tedavinin
etkinli¤i aras›nda fark bulunmad› (P = 0.537).
Sonuç: Klomipramin, Sertralin ve Terazosin plasebo’dan daha etkili idi. Üç medikal tedavi aras›nda etkinlik
yönünden farkl›l›k gözlenmedi.
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Premature ejaculation (PE) is a very common sexual dysfunction in the male
population, affecting 30% to 40% of sexually active men in an age-dependent manner
(1). This condition may be normal and temporary in adolescents, inexperienced men and
in men who have abstained from sex for a long time. Although the exact etiology of PE
is not well-understood, it is well known that ejaculation latency is precisely affected by
psychological, cognitive and somatic factors (2).
Numerous drugs and various techniques have been used to treat this sexual
dysfunction with varying degrees of success. Behavior therapy and psychological
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counseling are the initial approach. However, these
techniques require the active participation of both
partners, and some cultural and socioeconomic groups do
not participate in the therapies. Hence, some
pharmacological agents such as tricyclic antidepressants,
selective serotonin re-uptake inhibitors (SSRIs), topical
anesthetic agents, and sildenafil citrate are recommended
in the treatment of PE (3,4).
Ejaculation is mediated partly through a neural reflex
stimulated by sensory input to the penis and terminating
in smooth and striated muscle contractions that produce
seminal emission and ejaculation (1,2). Since emission
and ejaculation in normal men are mainly under the
control of the sympathetic nervous system, sympatholytic
agents have been used in the treatment of PE (5,6).
In the present study, we prospectively compared the
efficacies of clomipramine, sertraline and terazosin with
that of placebo in PE treatment.

Materials and Methods
Ninety patients 20 to 58 years old complaining of PE
presented to our outpatient clinic. The study was a single
blinded study. PE was defined according to the
International Classification of Diseases of the World
Health Organization-Version 10 as the inability to control
ejaculation sufficiently for both partners to enjoy sexual
interaction (7). All men were either married or had been
in a stable relationship with a female sexual partner for at
least 12 months.
Duration of PE in the patients ranged from 9 to 72
months (mean: 33.4 ± 18.6) and indicated the length of
time that the patients considered PE as an important
sexual problem.
All the patients underwent preliminary assessment
including a medical and sexual history, self-administration
of the first five questions of the International Index of
Erectile Function (IIEF) questionnaire (8), and physical
examination. Routine urine analysis, urine culture and
prostate fluid examination were performed to exclude
genital tract infection.
Study exclusion criteria were erectile dysfunction
according to the first five questions of the IIEF (score
<21), alcohol and drug abuse, mental retardation, low
libido, orthostatic hypotension, thyroid disease, previous
use of any drugs for PE, recent history of myocardial
60
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infarction, uncontrolled diabetes mellitus, previous
history of major depression including other psychiatric or
psychological illness, previous history of organic illness
causing limitations in selective SSRIs use, and presence of
organic disorders such as prostatitis or genital tract
infection.
The 90 patients were randomized into four groups.
Group 1 (n: 22) took placebo and served as controls.
Group 2 (n: 23) patients took one tablet of 25 mg
clomipramine HCl (Anafranil®, Geigy Inc.) (tricyclic
antidepressant) nightly; Group 3 (n: 20) one capsule of
®
50 mg sertraline (Lustral , Pfizer Inc.) (SSRI) nightly;
and Group 4 (n: 25) one tablet of 5 mg terazosin
®
(Hytrin , Abbott Inc.) (alpha-1 blocker) nightly. The
medications were used in all patients for two months. All
patients provided informed consent.
After eight sexual attempts, the patients’ clinical
responses were assessed based on the patient selfdescription method. Their clinical responses were
classified as “no change”, “improvement” and “under
control”. Under control was defined as ejaculation delayed
until desired by the patient and improvement was defined
as an increase in ejaculation time compared to pretreatment time. Success was described as improvement +
under control. Side effects were recorded.
Statistical Analysis
Statistical analysis was performed with the Statistical
Package for Social Sciences (SPSS) for Windows 8.0
software. The difference in age among the groups was
calculated using one-way ANOVA test. Subsequently, the
effectiveness and side effects of the treatment
alternatives were compared using Pearson correlation
test. A p value of less than 0.05 was considered
significant.

Results
Mean age of patients was 37.6 ± 8.1 years. The
median age in Groups 1, 2, 3 and 4 were 34.9 ± 9.0,
36.2 ± 7.4, 36.9 ± 6.9 and 41.8 ± 7.6 years,
respectively (one-way ANOVA test, P = 0.018).
Improvement and under control ratios in each group
are given in Table 1. Success rates were 36.3% in Group
1 (8/22), 91.3% in Group 2 (21/23), 90% in Group 3
(18/20) and 76% in Group 4 (19/25). Although medical
treatment efficacies were superior to placebo (Pearson χ2
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Table 1. Treatment results.

TREATMENT RESULTS
GROUPS

No change n (%)

Improvement n (%)

Under control n (%)

TOTAL n (%)

Group 1
(Placebo)

14 (63.7)

5 (22.7)

3 (13.6)

22 (100)

Group 2
(Clomipramine)

2 (8.7)

10 (43.5)

11 (47.8)

23 (100)

Group 3
(Sertraline)

2 (10.0)

7 (35.0)

11 (55.0)

20 (100)

Group 4
(Terazosin)

6 (24.0)

9 (36.0)

10 (40.0)

25 (100)

Others specify the number of penile thrusts, considering
8 to 15 thrusts as a criterion for PE (12). These cut-off
points mentioned above for ejaculation time and thrust
number were not derived from objective measurements
but were subjectively chosen by the different authors.
The absence of a clear, popular and widely accepted
definition of PE allows a “patient-dependent” definition
and a “patient-decided” diagnosis (13). Stopwatch is an
objective method introduced in 1983 for measuring the
outcome of the treatment results in PE. Although this
method has been widely accepted to define PE and
treatment response (14), in our country, the patients can
not regularly use this method because it requires active
involvement between patients and their partners. Hence,
we preferred using the patient self-description method
for assessing the treatment success.

= 23.075, P = 0.001), no significant difference was
found in terms of efficacy between the medical treatment
groups (Pearson χ2=3.123, P = 0.537).
None of the antidepressants had clinically relevant
effects on sexual desire, arousal, erectile function or
penile rigidity. The side effects are given in Table 2.
Headache, hypotension, ejaculation disorder and
drowsiness were the major side effects observed in our
patients. There were statistically significant differences
between the active treatment groups and the placebo
group with respect to these side effects (Pearson χ2 =
22.971, P = 0.028). However, there were no significant
differences in terms of the side effects between the
medical treatment groups (Pearson χ2 = 10.959, P =
0.204).

Neurologically, the ejaculatory process is under the
control of the central and peripheral nervous systems.
The anterior hypothalamus is the probable region of
central control of ejaculation. Within the central nervous
system, serotonin seems to be an inhibitory agent on

Discussion
There is no consensus about the definition of PE.
Depending on the study, any ejaculation occurring within
1 to 7 minutes has been considered as premature (9-11).

Table 2. Side effects.

SIDE EFFECTS

Headache
Hypotension
Drowsiness
Ejaculation disorder
TOTAL

Group 1(Placebo)
(n = 22)

Group 2 (Clomipramine)
(n = 23)

Group 3 (Sertraline)
(n = 20)

Group 4 (Terazosin)
(n = 25)

2
-

8
1
2
-

5
3
-

5
3
2

2/22 (9.1%)

11/23 (47.8%)

8/20 (40%)

10/25 (4%)
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ejaculatory function (15). A study by Lorrain et al. (16)
suggested that the observed increase in extracellular
serotoninergic system (5-HT) in both the anterior lateral
hypothalamus and medial preoptic area of male rats
following ejaculation may suppress subsequent ejaculation
and is responsible for the ejaculatory refractory period.
Different 5-HT receptor subtypes have an impact on
sexual
function.
Animal
and
human
psychopharmacological studies showed that PE is related
to decreased central serotonergic neurotransmission, 5HT2C receptor hyposensitivity and/or 5-HT1A receptor
hypersensitivity. Treatment should provide 5-HT2C
receptor stimulation and/or 5-HT1A inhibition (3,17).
Also, Berendsen and Broekkamp (18) reported that
activation of 5-HT1A receptors in male rats with a
selective agonist shortens the ejaculatory latency time. 5HT2C receptor stimulating with antidepressants exerted
an ejaculation delay.
The medial preoptic area in the rostral hypothalamus
and nucleus paragigantocellularis in the ventral medulla
are suggested to have important roles in the process
leading toward ejaculation. Electrical stimulation of the
medial preoptic area promotes ejaculation. Ejaculation is
tonically inhibited by serotonergic pathways descending
from the nucleus paragigantocellularis to the lumbosacral
motor nuclei. Disinhibition of the nucleus
paragigantocellularis is supposed to lead to ejaculation
(3,19).
The tricyclic antidepressant clomipramine has been
shown to be effective in treating PE with different doses
in several studies. Possible mechanisms for action of
clomipramine include inhibition of the ejaculatory reflex,
diminished psychologic arousal and anxiolytic effect (15).
In a study by Kim et al. (20), clomipramine was shown to
have the strongest inhibitory effect compared to the
other SSRIs such as fluoxetine, sertraline, and paroxetine
on hypogastric nerve stimulation-induced seminal vesicle
pressure. Segraves and associates (21) showed a dosedependent increase in intravaginal ejaculatory latency
time (IELT), which was superior in the clomipramine
group compared to placebo group. A study by Haensel
and co-workers (22) reported that “on demand”
clomipramine taken 12 to 24 hours before sexual activity
was more effective than placebo.
The SSRIs enhance 5-HT neurotransmission and
activate 5-HT receptors by blocking presynaptic and
somatodendritic 5-HT re-uptake transporter receptors
62
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(23). SSRIs have been shown to delay ejaculation in
several placebo-controlled randomized studies. In one
study, sertraline treatment produced significant
improvements relative to placebo in time to ejaculation
and number of successful attempts at intercourse (24).
Balbay et al. (25) reported that 68.7% of the patients
who used 50 mg sertraline had improved ejaculatory
control at the end of the second week. Another study
(26) showed that the mean IELT was significantly
improved after four weeks of sertraline treatment when
compared to placebo.
In the present study, clomipramine and sertraline
resulted in improved ejaculatory control in comparison to
placebo. Nevertheless, we did not find a significant
difference in effectiveness between clomipramine and
sertraline. Clomipramine and sertraline are safe
treatment options in rejection of or in conjunction with
psychological treatment for PE. Comparison between the
two types of antidepressants showed the higher efficacy
of clomipramine, although it had more side effects (27).
This is not found in our study. The most common side
effects of clomipramine and sertraline are drowsiness,
dry mouth, dizziness, dyspepsia, anejaculation, reduced
libido, constipation and fatigue (22,26,27). In the
present study, we did not detect any serious side effects
in relation to either clomipramine or sertraline usage. The
two types of medical agents were well tolerated by our
patients and none of these side effects (hypotension,
headache and drowsiness) was severe enough to stop the
treatment.
In morphological and psychological experimental
studies, it has been shown that the noradrenergic system,
through ascending pathway to the brain and descending
pathways to the spinal cord, and alpha-1 adrenoreceptors
may regulate sexual function (1,3). Many studies have
been conducted to identify alpha-1 adrenoreceptors
mediating contraction in male accessory sex organs.
Alpha-1 adrenoreceptors have been demonstrated in rat
vas deferens and prostate (28,29). It is also known that
alpha-1 adrenoreceptors play a role in the contraction of
the seminal vesicle induced by catecholamines (30). The
emission phase is regulated by the adrenergic system and
by the release of norepinephrine. Alpha-receptor
activation in the vas deferens, epididymis, prostate, and
seminal vesicles facilitates copulation, emission and
ejaculation. Blockage of the sympathetic ganglia by
ganglionic blockers can lead to ejaculatory failure due to
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inhibition of contractions of the seminal vesicle, ampulla
and ductus deferens (13). Kim and co-workers (20)
observed that alpha-adrenergic blockers inhibited both
intraluminal seminal vesicle and vas deferens pressure
responses in a concentration-dependent manner.
Alpha blockers seem to be the most suitable medical
treatment option in PE based on ejaculation physiology in
patients with lower urinary tract symptoms. Cavallini (5)
reported that efficacies of the alpha-blocker agents such
as alfuzosin and terazosin were 50% in PE unresponsive
to psychological approach. Another study (6) showed that
sympatholytic agents inhibited the contractile response of
rat seminal vesicle to electrical nerve stimulation in an
animal study. Furthermore, this study strongly suggested
clinical usage of alpha-blockers because of their
comparable potency with different agents.
In the present study, terazosin was found to be more
effective than placebo (76% vs 36.3%). Nevertheless, no
significant differences in efficacy were determined among
the three drugs. Side effects of alpha-blockers are
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impeded orgasm, dry mouth, nasal congestion,
drowsiness and fatigue. However, these have been rarely
observed in therapeutic doses. The other important side
effect of alpha-blockers is impaired ejaculation or
retrograde ejaculation. However, with the exception of
tamsulosin, no cases of abnormal ejaculation have been
reported with alpha-blockers (31). In our study, no
significant difference was found in terms of the side
effects between terazosin and the other antidepressant
drugs. Hypotension, headache and ejaculation disorder
were the most common side effects related to terazosin
usage. No side effects of terazosin causing treatment
cessation were observed in the patients.
In conclusion, clomipramine, sertraline and terazosin
are more efficient than placebo in PE treatment. These
three treatment modalities demonstrated equal efficacy
with the same rates of side effects and each of them was
well tolerated by our patients. Each medical agent
mentioned above can be used with the same efficacy and
side effects, and can be chosen according to individual
preference.
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